PL379887A1 - Sposób leczenia raka inhibitorami HDAC - Google Patents
Sposób leczenia raka inhibitorami HDACInfo
- Publication number
- PL379887A1 PL379887A1 PL379887A PL37988704A PL379887A1 PL 379887 A1 PL379887 A1 PL 379887A1 PL 379887 A PL379887 A PL 379887A PL 37988704 A PL37988704 A PL 37988704A PL 379887 A1 PL379887 A1 PL 379887A1
- Authority
- PL
- Poland
- Prior art keywords
- hdac inhibitors
- pharmaceutical compositions
- present
- methods
- mesothelioma
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
- C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
- Prostheses (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Diaphragms For Electromechanical Transducers (AREA)
- Electrotherapy Devices (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/650,025 US7148257B2 (en) | 2002-03-04 | 2003-08-26 | Methods of treating mesothelioma with suberoylanilide hydroxamic acid |
US10/665,079 US20040127523A1 (en) | 2002-03-04 | 2003-09-16 | Methods of treating cancer with HDAC inhibitors |
PCT/US2004/027943 WO2005018578A2 (en) | 2003-08-26 | 2004-08-26 | Method of treating cancer with hdac inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
PL379887A1 true PL379887A1 (pl) | 2006-11-27 |
Family
ID=34556614
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL04782425T PL1663194T3 (pl) | 2003-08-26 | 2004-08-26 | Zastosowanie SAHA do leczenia międzybłoniaka |
PL379887A PL379887A1 (pl) | 2003-08-26 | 2004-08-26 | Sposób leczenia raka inhibitorami HDAC |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL04782425T PL1663194T3 (pl) | 2003-08-26 | 2004-08-26 | Zastosowanie SAHA do leczenia międzybłoniaka |
Country Status (23)
Country | Link |
---|---|
US (1) | US20090012175A1 (pl) |
EP (2) | EP1663194B1 (pl) |
JP (2) | JP4338734B2 (pl) |
KR (1) | KR100924737B1 (pl) |
CN (1) | CN102188415A (pl) |
AT (1) | ATE462426T1 (pl) |
AU (1) | AU2004266169B9 (pl) |
BR (1) | BRPI0413826A (pl) |
CA (1) | CA2535806C (pl) |
DE (1) | DE602004026321D1 (pl) |
DK (1) | DK1663194T3 (pl) |
EC (1) | ECSP066452A (pl) |
ES (1) | ES2345775T3 (pl) |
HR (1) | HRP20060080A2 (pl) |
IL (1) | IL173846A0 (pl) |
MA (1) | MA28209A1 (pl) |
NO (1) | NO328575B1 (pl) |
NZ (2) | NZ560485A (pl) |
PL (2) | PL1663194T3 (pl) |
PT (1) | PT1663194E (pl) |
RU (1) | RU2356547C2 (pl) |
SI (1) | SI1663194T1 (pl) |
WO (1) | WO2005018578A2 (pl) |
Families Citing this family (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6777217B1 (en) | 1996-03-26 | 2004-08-17 | President And Fellows Of Harvard College | Histone deacetylases, and uses related thereto |
US20030129724A1 (en) | 2000-03-03 | 2003-07-10 | Grozinger Christina M. | Class II human histone deacetylases, and uses related thereto |
US7244853B2 (en) | 2001-05-09 | 2007-07-17 | President And Fellows Of Harvard College | Dioxanes and uses thereof |
US20040132825A1 (en) * | 2002-03-04 | 2004-07-08 | Bacopoulos Nicholas G. | Methods of treating cancer with HDAC inhibitors |
US20040072735A1 (en) * | 2002-03-04 | 2004-04-15 | Richon Victoria M. | Methods of inducing terminal differentiation |
US7456219B2 (en) * | 2002-03-04 | 2008-11-25 | Merck Hdac Research, Llc | Polymorphs of suberoylanilide hydroxamic acid |
EP1501489A4 (en) * | 2002-04-15 | 2007-11-21 | Sloan Kettering Inst Cancer | COMBINATION THERAPY FOR THE TREATMENT OF CANCER |
WO2004089293A2 (en) | 2003-04-01 | 2004-10-21 | Memorial Sloan-Kettering Cancer Center | Hydroxamic acid compounds and methods of use thereof |
US7901675B2 (en) * | 2004-10-13 | 2011-03-08 | U.S. Department Of Veterans Affairs | Method of using coenzyme Q10 to treat Huntington's disease |
US20060135612A1 (en) * | 2004-12-17 | 2006-06-22 | U.S. Department Of Veterans Affairs | Method of ameliorating or abrogating the effects of a neurodegenerative disorder, such as amyotrophic lateral sclerosis (ALS), by using a HDAC inhibiting agent |
EP2522397A1 (en) | 2005-02-03 | 2012-11-14 | TopoTarget UK Limited | Combination therapies using HDAC inhibitors |
JP5744376B2 (ja) | 2005-03-22 | 2015-07-08 | プレジデント アンド フェローズ オブ ハーバード カレッジ | タンパク質分解障害の治療 |
GB0509225D0 (en) | 2005-05-05 | 2005-06-15 | Chroma Therapeutics Ltd | Inhibitors of enzymatic activity |
GB0509223D0 (en) | 2005-05-05 | 2005-06-15 | Chroma Therapeutics Ltd | Enzyme inhibitors |
DK1901729T3 (da) | 2005-05-13 | 2012-05-14 | Topotarget Uk Ltd | Farmaceutiske formuleringer af HDAC-inhibitorer |
TWI365068B (en) | 2005-05-20 | 2012-06-01 | Merck Sharp & Dohme | Formulations of suberoylanilide hydroxamic acid and methods for producing same |
WO2007011626A2 (en) | 2005-07-14 | 2007-01-25 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
GB0518720D0 (en) * | 2005-09-14 | 2005-10-19 | Hamlet Pharma Ab | Therapeutic combination |
AU2006311829B8 (en) * | 2005-11-04 | 2013-02-21 | Merck Sharp & Dohme Corp. | Methods of treating cancers with SAHA, Carboplatin, and Paclitaxel and other combination therapies |
WO2007056243A2 (en) * | 2005-11-04 | 2007-05-18 | Merck & Co. Inc. | Methods of treating cancers with saha and fluorouracil and other combination therapies |
CA2636596A1 (en) * | 2005-11-04 | 2007-05-18 | James Pluda | Method of treating cancers with saha and pemetrexed |
CA2627923C (en) * | 2005-11-10 | 2016-01-12 | Topotarget Uk Limited | Histone deacetylase (hdac) inhibitors (pxdlol) for the treatment of cancer |
WO2007095584A2 (en) | 2006-02-14 | 2007-08-23 | The President And Fellows Of Harvard College | Histone Deacetylase Inhibitors |
JP5441416B2 (ja) * | 2006-02-14 | 2014-03-12 | プレジデント アンド フェロウズ オブ ハーバード カレッジ | 二官能性ヒストンデアセチラーゼインヒビター |
EP2012801A4 (en) | 2006-04-24 | 2009-08-05 | Gloucester Pharmaceuticals Inc | GEMCITABINE COMBINATION THERAPY |
WO2007130429A2 (en) | 2006-05-03 | 2007-11-15 | The President And Fellows Of Harvard College | Histone deacetylase and tubulin deacetylase inhibitors |
US8957027B2 (en) | 2006-06-08 | 2015-02-17 | Celgene Corporation | Deacetylase inhibitor therapy |
GB0619753D0 (en) | 2006-10-06 | 2006-11-15 | Chroma Therapeutics Ltd | Enzyme inhibitors |
US8962825B2 (en) | 2006-10-30 | 2015-02-24 | Glaxosmithkline Intellectual Property Development Limited | Hydroxamates as inhibitors of histone deacetylase |
US20100113392A1 (en) * | 2006-11-03 | 2010-05-06 | Badros Ashraf Z | Methods of using saha and bortezomib for treating multiple myeloma |
MX2009006969A (es) | 2006-12-29 | 2010-04-07 | Gloucester Pharmaceuticals | Purificacion de romidepsina. |
EP2203421B1 (en) * | 2007-09-25 | 2014-05-07 | TopoTarget UK Limited | Methods of synthesis of certain n-hydroxy-3-(3-phenylsulfamoyl-phenyl)-acrylamide compounds |
WO2009064300A1 (en) * | 2007-11-15 | 2009-05-22 | The Johns Hopkins University | Combinations of hdac inhibitors and cytokines/growth factors |
MX2010009642A (es) * | 2008-03-07 | 2010-09-22 | Topotarget As | Metodos de tratamiento utilizando infusion continua prolongada de belinostat. |
KR101708946B1 (ko) | 2008-07-23 | 2017-02-21 | 다나-파버 캔서 인스티튜트 인크. | 탈아세틸화제 억제제 및 그것의 용도 |
CN102264694B (zh) | 2008-10-15 | 2015-11-25 | 基因里克斯(英国)有限公司 | 用于制备伏立诺他的方法 |
WO2010061219A2 (en) | 2008-11-26 | 2010-06-03 | Generics [Uk] Limited | Polymorphs |
GB0900555D0 (en) * | 2009-01-14 | 2009-02-11 | Topotarget As | New methods |
GB0903480D0 (en) | 2009-02-27 | 2009-04-08 | Chroma Therapeutics Ltd | Enzyme Inhibitors |
WO2011019393A2 (en) | 2009-08-11 | 2011-02-17 | President And Fellows Of Harvard College | Class- and isoform-specific hdac inhibitors and uses thereof |
WO2011160206A1 (en) | 2010-06-23 | 2011-12-29 | Morin Ryan D | Biomarkers for non-hodgkin lymphomas and uses thereof |
SG187032A1 (en) | 2010-07-12 | 2013-02-28 | Celgene Corp | Romidepsin solid forms and uses thereof |
US9175331B2 (en) | 2010-09-10 | 2015-11-03 | Epizyme, Inc. | Inhibitors of human EZH2, and methods of use thereof |
US8895245B2 (en) * | 2010-09-10 | 2014-11-25 | Epizyme, Inc. | Inhibitors of human EZH2 and methods of use thereof |
US8859502B2 (en) | 2010-09-13 | 2014-10-14 | Celgene Corporation | Therapy for MLL-rearranged leukemia |
JO3438B1 (ar) | 2011-04-13 | 2019-10-20 | Epizyme Inc | مركبات بنزين مستبدلة بأريل أو أريل غير متجانس |
CN102846611A (zh) * | 2011-09-24 | 2013-01-02 | 复旦大学 | 斯克瑞泰Scriptaid在制备治疗创伤性脑损伤疾病药物中的用途 |
AU2013202506B2 (en) | 2012-09-07 | 2015-06-18 | Celgene Corporation | Resistance biomarkers for hdac inhibitors |
CN110041250A (zh) | 2012-10-15 | 2019-07-23 | Epizyme股份有限公司 | 经取代的苯化合物 |
AU2013202507B9 (en) | 2012-11-14 | 2015-08-13 | Celgene Corporation | Inhibition of drug resistant cancer cells |
CN103169807A (zh) * | 2013-04-11 | 2013-06-26 | 太仓市胜舟生物技术有限公司 | 一种中西组合药物在制药中的应用 |
NZ630311A (en) | 2013-12-27 | 2016-03-31 | Celgene Corp | Romidepsin formulations and uses thereof |
WO2015190700A1 (ko) * | 2014-06-11 | 2015-12-17 | 성균관대학교산학협력단 | 패혈증 예방 또는 치료용 약학적 조성물 |
CN111195249B (zh) * | 2018-11-20 | 2023-11-28 | 深圳微芯生物科技股份有限公司 | 西达本胺联合r-chop的应用及联合药物 |
Family Cites Families (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
JPS61176523A (ja) * | 1985-01-30 | 1986-08-08 | Teruhiko Beppu | 制癌剤 |
US5055608A (en) | 1988-11-14 | 1991-10-08 | Sloan-Kettering Institute For Cancer Research | Novel potent inducers of thermal differentiation and method of use thereof |
US5175191A (en) | 1988-11-14 | 1992-12-29 | Sloan-Kettering Institute For Cancer Research | Potent inducers of terminal differentiation and methods of use thereof |
US5608108A (en) | 1988-11-14 | 1997-03-04 | Sloan-Kettering Institute For Cancer Research | Potent inducers of terminal differentiation and method of use thereof |
USRE38506E1 (en) * | 1991-10-04 | 2004-04-20 | Sloan-Kettering Institute For Cancer Research | Potent inducers of terminal differentiation and methods of use thereof |
US5369108A (en) | 1991-10-04 | 1994-11-29 | Sloan-Kettering Institute For Cancer Research | Potent inducers of terminal differentiation and methods of use thereof |
US5700811A (en) | 1991-10-04 | 1997-12-23 | Sloan-Kettering Institute For Cancer Research | Potent inducers of terminal differentiation and method of use thereof |
US5635532A (en) * | 1991-10-21 | 1997-06-03 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Compositions and methods for therapy and prevention of pathologies including cancer, AIDS and anemia |
AU712801B2 (en) | 1995-09-20 | 1999-11-18 | Merck Sharp & Dohme Corp. | Histone deacetylase as target for antiprotozoal agents |
US6043389A (en) * | 1997-03-11 | 2000-03-28 | Mor Research Applications, Ltd. | Hydroxy and ether-containing oxyalkylene esters and uses thereof |
US6030961A (en) | 1997-03-11 | 2000-02-29 | Bar-Ilan Research & Development Co., Ltd. | Oxyalkylene phosphate compounds and uses thereof |
US6387673B1 (en) | 1997-05-01 | 2002-05-14 | The Salk Institute For Biological Studies | Compounds useful for the modulation of processes mediated by nuclear hormone receptors, methods for the identification and use of such compounds |
US6231880B1 (en) * | 1997-05-30 | 2001-05-15 | Susan P. Perrine | Compositions and administration of compositions for the treatment of blood disorders |
US6262116B1 (en) * | 1998-01-23 | 2001-07-17 | Sloan-Kettering Institute For Cancer Research | Transcription therapy for cancers |
AUPP505798A0 (en) | 1998-08-04 | 1998-08-27 | Fujisawa Pharmaceutical Co., Ltd. | Novel compound fr225497 substance |
TR200101049T2 (tr) | 1998-10-13 | 2002-01-21 | Fujisawa Pharmaceutical Co. Ltd. | Siklik tetrapeptid bileşiği ve kullanımı |
JP2003500052A (ja) | 1999-05-03 | 2003-01-07 | メチルジーン インコーポレイテッド | ヒストン脱アセチル酵素の抑制 |
NZ517613A (en) | 1999-09-08 | 2004-01-30 | Sloan Kettering Inst Cancer | Novel class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof |
PT1233958E (pt) | 1999-11-23 | 2011-09-20 | Methylgene Inc | Inibidores de histona desacetilase |
JP2003528074A (ja) | 2000-03-24 | 2003-09-24 | メチルジーン インコーポレイテッド | ヒストン脱アセチル化酵素の阻害剤 |
PE20020354A1 (es) | 2000-09-01 | 2002-06-12 | Novartis Ag | Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda) |
AU2001287157A1 (en) * | 2000-09-12 | 2002-03-26 | Virginia Commonwealth University | Promotion of adoptosis in cancer cells by co-administration of cyclin dependent kinase inhibitors and cellular differentiation agents |
WO2002030879A2 (en) | 2000-09-29 | 2002-04-18 | Prolifix Limited | Carbamic acid compounds comprising a sulfonamide linkage as hdac inhibitors |
AU2002243231A1 (en) * | 2000-11-21 | 2002-07-24 | Wake Forest University | Method of treating autoimmune diseases |
AR035659A1 (es) | 2000-12-07 | 2004-06-23 | Hoffmann La Roche | Hidroxiamidas de acido (1-oxo-1,2,3,4-tetrahidro-naftalen-2-il)-alcanoico, proceso para la manufactura de estos compuestos, composiciones farmaceuticas que contienen dichos compuestos y los usos de los mismos |
US6495719B2 (en) * | 2001-03-27 | 2002-12-17 | Circagen Pharmaceutical | Histone deacetylase inhibitors |
US6905669B2 (en) * | 2001-04-24 | 2005-06-14 | Supergen, Inc. | Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase |
US7199227B2 (en) * | 2001-06-14 | 2007-04-03 | Bristol-Myers Squibb Company | Polynucleotides encoding human histone deacetylase HDAC9c |
ITMI20011733A1 (it) * | 2001-08-07 | 2003-02-07 | Italfarmaco Spa | Derivati dell'acido idrossamico inibitori degli enzimi istone deacetilasi, quali nuovi farmaci antiinfiammatori inibenti la sintesi di citoc |
US20040132643A1 (en) * | 2002-01-09 | 2004-07-08 | Fojo Antonio Tito | Histone deacelylase inhibitors in diagnosis and treatment of thyroid neoplasms |
AU2003219803B8 (en) * | 2002-02-15 | 2005-08-25 | Sloan-Kettering Institute For Cancer Research | Method of treating TRX mediated diseases |
US20060276547A1 (en) * | 2002-03-04 | 2006-12-07 | Bacopoulos Nicholas G | Methods of treating cancer with HDAC inhibitors |
US7148257B2 (en) * | 2002-03-04 | 2006-12-12 | Merck Hdac Research, Llc | Methods of treating mesothelioma with suberoylanilide hydroxamic acid |
US7456219B2 (en) * | 2002-03-04 | 2008-11-25 | Merck Hdac Research, Llc | Polymorphs of suberoylanilide hydroxamic acid |
US20040132825A1 (en) * | 2002-03-04 | 2004-07-08 | Bacopoulos Nicholas G. | Methods of treating cancer with HDAC inhibitors |
US20040072735A1 (en) * | 2002-03-04 | 2004-04-15 | Richon Victoria M. | Methods of inducing terminal differentiation |
EP1501489A4 (en) * | 2002-04-15 | 2007-11-21 | Sloan Kettering Inst Cancer | COMBINATION THERAPY FOR THE TREATMENT OF CANCER |
WO2004046104A2 (en) * | 2002-11-20 | 2004-06-03 | Errant Gene Therapeutics, Llc | Treatment of lung cells with histone deacetylase inhibitors |
WO2004089293A2 (en) * | 2003-04-01 | 2004-10-21 | Memorial Sloan-Kettering Cancer Center | Hydroxamic acid compounds and methods of use thereof |
US20050043233A1 (en) * | 2003-04-29 | 2005-02-24 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis |
-
2004
- 2004-08-26 CN CN201110072778XA patent/CN102188415A/zh active Pending
- 2004-08-26 WO PCT/US2004/027943 patent/WO2005018578A2/en active IP Right Grant
- 2004-08-26 AT AT04782425T patent/ATE462426T1/de active
- 2004-08-26 AU AU2004266169A patent/AU2004266169B9/en active Active
- 2004-08-26 PT PT04782425T patent/PT1663194E/pt unknown
- 2004-08-26 NZ NZ560485A patent/NZ560485A/en not_active IP Right Cessation
- 2004-08-26 BR BRPI0413826-0A patent/BRPI0413826A/pt not_active IP Right Cessation
- 2004-08-26 RU RU2006109467/14A patent/RU2356547C2/ru not_active IP Right Cessation
- 2004-08-26 ES ES04782425T patent/ES2345775T3/es active Active
- 2004-08-26 PL PL04782425T patent/PL1663194T3/pl unknown
- 2004-08-26 EP EP04782425A patent/EP1663194B1/en active Active
- 2004-08-26 KR KR1020067003748A patent/KR100924737B1/ko not_active IP Right Cessation
- 2004-08-26 DK DK04782425.5T patent/DK1663194T3/da active
- 2004-08-26 CA CA002535806A patent/CA2535806C/en not_active Expired - Fee Related
- 2004-08-26 EP EP10158245A patent/EP2201947A3/en not_active Withdrawn
- 2004-08-26 PL PL379887A patent/PL379887A1/pl unknown
- 2004-08-26 NZ NZ54593504A patent/NZ545935A/xx not_active IP Right Cessation
- 2004-08-26 SI SI200431448T patent/SI1663194T1/sl unknown
- 2004-08-26 DE DE602004026321T patent/DE602004026321D1/de active Active
- 2004-08-26 JP JP2006524891A patent/JP4338734B2/ja not_active Expired - Fee Related
-
2006
- 2006-02-21 IL IL173846A patent/IL173846A0/en unknown
- 2006-02-23 MA MA28833A patent/MA28209A1/fr unknown
- 2006-02-23 HR HR20060080A patent/HRP20060080A2/xx not_active Application Discontinuation
- 2006-03-23 EC EC2006006452A patent/ECSP066452A/es unknown
- 2006-03-24 NO NO20061348A patent/NO328575B1/no not_active IP Right Cessation
-
2008
- 2008-07-08 US US12/217,843 patent/US20090012175A1/en not_active Abandoned
- 2008-09-11 JP JP2008232889A patent/JP4914411B2/ja not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20060080A2 (en) | Method of treating cancer with hdac inhibitors | |
WO2005039498A3 (en) | Methods of treating cancer with hdac inhibitors | |
WO2003075839A3 (en) | Methods of inducing terminal differentiation | |
HK1096034A1 (en) | A solid dosage form comprising a fibrate | |
TW200510375A (en) | New compounds | |
EP1961748A3 (en) | 2-Hydroxy-3-heteroarylindole derivatives as GSK3 inhibitors | |
DE602005021770D1 (de) | Indol-1-yl-essigsäurederivate | |
TNSN07322A1 (en) | Pyrimidine derivatives for treatment of hyperproliferative disorders | |
MXPA05008838A (es) | Formulaciones de absorcion acelerada del agonista selectivo de la 5-ht. | |
MY140840A (en) | Acylated, heteroaryl-condensed cycloalkenylamines and their use as pharmaceuticals | |
UA90893C2 (ru) | Пероральная дозированная форма производных гемцитабина | |
MXPA05011076A (es) | Derivados de quinazolina para el tratamiento de cancer. | |
SI1730144T1 (sl) | Substituirane spojine 1,4,8-triazaspiro(4.5)dekan-2-on | |
WO2007064448A3 (en) | Cancer treatment using fts and 2-deoxyglucose | |
TW200505452A (en) | Chemical compounds | |
CY1110659T1 (el) | Χρησιμοποιηση toy saha για την θεραπευτικη αγωγη μεσοθηλιωματος | |
AU2001246388A1 (en) | Controlled release pharmaceutical composition containing midodrine and/or desglymidodrine | |
EA200600998A1 (ru) | Фармацевтическая композиция, содержащая цинк-гиалуронановый комплекс, предназначенная для лечения рассеянного склероза | |
TW200728296A (en) | Chemical compounds | |
SE0203817D0 (sv) | New composition | |
WO2006121857A3 (en) | Unsolvated and host-guest solvated crystalline forms of (2e,4s)-4-[(n-{[(2r)-1-isopropylpiperidin-2-yl]-carbonyl}-3-methyl-l-valyl)(methyl)amino]-2,5-dimethylhex-2-enoic acid and their pharmaceutical uses | |
TW200509902A (en) | Pharmaceutical formulation for the treatment of overactive bladder | |
WO2005035500A3 (en) | Therapeutic agents useful for treating pain | |
HUP0103459A2 (hu) | (2S,3S,5R)-2-(3,5-difluorfenil)-3,5-dimetil-2-morfolinol tartalmú, orális adagolási formák hatékony mennyiségű stabilizáló alginsavval | |
UA54880C2 (uk) | Застосування (s)-2-аміно-5-гуанідинопентанової кислоти (s)-2-аміноглутарату (l-аргініну l-глутамат) як фармацевтичного препарату, що має гепатопротекторну та детоксикуючу дію, спосіб його одержання, фармацевтична композиція на його основі |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
DISC | Decisions on discontinuance of the proceedings (taken after the publication of the particulars of the applications) |